Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Zydus Therapeutics Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05045482CT.gov Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cirrhosis Of Liver
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Saroglitazar (this asset) | Zydus Therapeutics Inc. | P1 | C · 39 |
| Veruprevir | AbbVie | P3 | A |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | General Hospital of Shenyang Military Region | P4 | BBB |
| Tolvaptan | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Ribavirin | Peking University People's Hospital | P4 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BBB |
| Ombitasvir | AbbVie | P3 | BBB |
| Carvedilol | West China Hospital | P4 | BBB |
| Telbivudine | Lin Bingliang | P4 | BBB |
+42 more in the Cirrhosis Of Liver cohort
Other indications for Saroglitazar
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Biliary Cholangitis | — | P3 | BB · 69 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BB · 68 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Saroglitazar in Cirrhosis Of Liver. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/saroglitazar-cirrhosis-of-liver
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →